文献速递MDS 与骨髓增殖性肿瘤

KT-253:高效选择性MDM2降解剂清除骨髓纤维化恶性干/祖细胞

KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells.
PubMed 文献 · Leukemia · 2026-10-06

约96%骨髓纤维化(MF)患者表达野生型p53,其造血干/祖细胞(HSPC)过表达MDM2以降解野生型p53并维持生存。研究评估MDM2降解剂KT-253在MPN细胞系、原代MF CD34+细胞及小鼠异种移植模型中的作用,发现其通过激活p53通路诱导凋亡,并在更低浓度下优于MDM2小分子抑制剂AMG-232,显著减少MF集落及JAK2V617F+集落和骨髓重建细胞。

要点

  • KT-253通过降解MDM2激活p53通路,诱导野生型p53的MF CD34+细胞凋亡。
  • KT-253在比AMG-232低十倍的浓度下即诱导原代MF CD34+细胞凋亡。
  • 低剂量KT-253减少MF集落和JAK2V617F+集落的效果远优于高剂量AMG-232。

核心结论

  • KT-253可高效清除MF造血干/祖细胞,支持进一步临床评估MDM2降解剂治疗MF。

研究设计与样本

  • 研究使用MPN细胞系、原代MF CD34+细胞和小鼠异种移植模型评估KT-253的作用。

主要发现

  • KT-253活性与野生型p53 UKE-1细胞中p53通路激活及p21、NOXA、PUMA等下游基因上调相关,而在p53突变细胞中无此效应。
  • KT-253在比AMG-232低十倍的浓度下诱导原代MF CD34+细胞凋亡,并阻止AMG-232所致的MDM2上调。
  • 低剂量KT-253使总MF集落和JAK2V617F+集落数分别减少60%和71%,而高对数级剂量的AMG-232仅减少20%和10%。
  • 小鼠异种移植研究显示KT-253更有效清除JAK2V617F+ MF骨髓重建细胞。

临床怎么用

  • KT-253作为MDM2降解剂,可能克服MDM2小分子抑制剂无法充分清除MF HSPC的局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 96% of myelofibrosis (MF) patients express wild-type (WT) p53. MF hematopoietic stem/progenitor cells (HSPCs) overexpress MDM2 that degrades WTp53, thereby supporting MF HSPC survival. Although MDM2 small-molecule inhibitors (SMIs) are clinically effective, their benefit is compromised by an inability to sufficiently deplete MF HSPCs. KT-253 degrades MDM2 and overcomes the p53-dependent feedback loop that restores MDM2 levels observed with the use of MDM2 SMIs such as AMG-232. We evaluated the effects of KT-253 using MPN cell lines, primary MF CD34+ cells, and a mouse xenograft model. KT-253 activity was correlated with activation of the p53 pathway and upregulation of p53 downstream genes, including p21, NOXA, and PUMA in WTp53 UKE-1 cells but not p53 mutant cells. KT-253 treatment induced apoptosis of primary MF CD34+ cells at a tenfold lower concentration than AMG-232 and prevented the upregulation of MDM2 seen with AMG-232. Low doses of KT-253 reduced total MF colony and JAK2V617F+ colony numbers to a far greater extent than log-higher doses of AMG-232 (60% and 71% versus 20% and 10%, respectively). Mouse xenograft studies indicated that KT-253 more effectively depleted JAK2V617F+ MF marrow-repopulating cells. These findings support the further clinical evaluation of MDM2 degraders for the treatment of MF patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lu M, Xia L, Chutake Y, et al. KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells. Leukemia. 2026. PMID: 42839074. doi:10.1038/s41375-026-03163-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。